TG Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$33.7M
Doctors Paid
5,174
Transactions
30,295
2024 Total
$10.7M
Payment Breakdown by Category
Research$25.2M (74.9%)
Consulting$1.6M (4.6%)
Travel$775,729 (2.3%)
Food & Beverage$685,563 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $25.2M | 7,867 | 74.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5.2M | 1,608 | 15.5% |
| Consulting Fee | $1.6M | 855 | 4.6% |
| Travel and Lodging | $775,729 | 1,535 | 2.3% |
| Food and Beverage | $685,563 | 18,277 | 2.0% |
| Space rental or facility fees (teaching hospital only) | $120,029 | 35 | 0.4% |
| Grant | $33,600 | 1 | 0.1% |
| Charitable Contribution | $30,000 | 2 | 0.1% |
| Education | $3,265 | 115 | 0.0% |
Payments by Type
Research
$25.2M
7,867 transactions
General
$8.4M
22,428 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| ULTRA-V: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL) | $7.1M | 0 | 1,748 |
| (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | $3.5M | 0 | 596 |
| TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | $2.9M | 0 | 570 |
| A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) | $2.6M | 0 | 1,686 |
| UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkins Lymphoma | $2.0M | 0 | 1,080 |
| UTX-TGR-203: A Phase II Study Evaluation the Safety and Efficacy of umbralisib (TGR-1202) in combination with ublituxaimb in Patients with Treatment Nave Follicular Lymphoma and Small Lymphocytic Lymphoma | $1.2M | 0 | 293 |
| An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 | $786,831 | 0 | 513 |
| Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax | $599,690 | 0 | 121 |
| (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | $571,954 | 0 | 104 |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | $543,012 | 0 | 154 |
| A Phase 2 Study of Acalabrutinib, Umbralisib and Ublituximab in Relapsed and Previously Untreated CLL Patients | $459,304 | 0 | 18 |
| Extension Trial of Ublituximab and Umbralisib (TGR-1202) in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | $329,949 | 0 | 436 |
| (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | $329,536 | 0 | 56 |
| Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma | $324,969 | 0 | 45 |
| Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | $305,688 | 0 | 20 |
| A Phase 2 Study to Assess the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Parameters of Umbralisib in Treatment Nave Patients with Chronic Lymphocytic Leukemia (CLL) | $209,625 | 0 | 9 |
| Retrospective Evaluation of Infusion Tolerability: BRIUMVI Real-World Observational Survey (ENAMOR) | $159,500 | 1 | 47 |
| A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination with Ibrutinib in Patients with Select B-Cell Malignancies | $136,805 | 0 | 10 |
| A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis. | $128,466 | 0 | 51 |
| (GENUINE) Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) | $121,184 | 0 | 33 |
| A Phase 2 Study of Acalabrutinib and PI3K inhibitor Umbralisib in Combination with Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma | $103,252 | 0 | 14 |
| Evaluate the Efficacy and Safety of TGR-1202 (Umbralisib) in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy | $100,784 | 0 | 50 |
| RMS301 | $84,879 | 10 | 56 |
| Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma | $79,011 | 0 | 12 |
| Phase I study of ublituximab and umbralisib in combination with targeted immunotherapy in patients with relapsed-refractory CLL or Richters transformation of CLL | $73,832 | 0 | 15 |
| RMS302 | $67,543 | 10 | 57 |
| Effects of Ublituximab on Unperturbed and Perturbed Ambulatory Functions in People with Relapsing Multiple Sclerosis | $65,817 | 0 | 1 |
| Ublituximab as initial therapy for treatment nave follicular or marginal zone lymphoma with response-driven addition of umbralisib for suboptimal response | $62,253 | 0 | 8 |
| An Open-Label, Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201 Treated with Ublituximab for Relapsing Forms of Multiple Sclerosis | $61,475 | 0 | 3 |
| Retrospective analysis of natalizumab switches to ublituximab in patients with relapsing multiple sclerosis (MS) | $52,260 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Sagar Lonial, M.d, M.D | Hematology | Atlanta, GA | $798,845 | $0 |
| Dr. Mary Ann Picone, Md, MD | Neurology | Teaneck, NJ | $211,742 | $0 |
| Kenneth Mankowski, Do, DO | Neurology | Columbus, OH | $152,734 | $0 |
| Barry Singer | Neurology | Saint Louis, MO | $131,922 | $0 |
| Aram Zabeti, M.d, M.D | Neurology | Cincinnati, OH | $130,830 | $0 |
| Derrick Robertson, M.d, M.D | Neurology | Tampa, FL | $125,165 | $0 |
| Dr. Stephen Krieger, Md, MD | Neurology | New York, NY | $117,752 | $0 |
| Daniel Bandari, M.d, M.D | Neurology | Newport Beach, CA | $112,696 | $0 |
| Dr. Mark Tullman, M.d, M.D | Neurology | Saint Louis, MO | $110,103 | $0 |
| Dr. Regina Berkovich, Md, MD | Neurology | West Hollywood, CA | $103,135 | $0 |
| Dr. Sangjin Oh, M.d, M.D | Neurology | Glen Burnie, MD | $96,438 | $0 |
| Dr. Daniel Becker, Md, MD | Spinal Cord Injury Medicine | Lutherville, MD | $96,369 | $0 |
| Katrina Bawden, Aprn, APRN | Family | Salt Lake City, UT | $91,200 | $0 |
| Kyle Smoot, M.d, M.D | Neurology | Portland, OR | $89,438 | $0 |
| Dr. Bhupendra Khatri, M.d, M.D | Neurology | Milwaukee, WI | $87,961 | $0 |
| Dr. Robert Shin, M.d, M.D | Neurology | Charlottesville, VA | $82,870 | $0 |
| Dr. Pavle Repovic, Md, Phd, MD, PHD | Neurology | Seattle, WA | $76,471 | $0 |
| William Conte, M.d, M.D | Neurology | Merrillville, IN | $76,172 | $0 |
| David Clark, Do, DO | Neurology | Springfield, OR | $76,017 | $0 |
| Dr. Nilay Shah, Md, MD | Clinical Neurophysiology | Fair Lawn, NJ | $75,203 | $0 |
| Douglas Stuart, M.d, M.D | Neurology | Atlanta, GA | $74,249 | $0 |
| Bruce Hughes, Md, MD | Neurology | Des Moines, IA | $74,152 | $0 |
| Matthew Carraro, M.d, M.D | Student in an Organized Health Care Education/Training Program | Charlotte, NC | $73,000 | $0 |
| Adnan Subei, D.o, D.O | Neurology | Dallas, TX | $72,620 | $0 |
| Barry Hendin, Md, MD | Neurology | Phoenix, AZ | $70,986 | $0 |
About TG Therapeutics, Inc.
TG Therapeutics, Inc. has made $33.7M in payments to 5,174 healthcare providers, recorded across 30,295 transactions in the CMS Open Payments database. In 2024, the company paid $10.7M. The top product by payment volume is UKONIQ ($16.5M).
Payments were distributed across 114 medical specialties. The top specialty by payment amount is Neurology ($5.3M to 1,871 doctors).
Payment categories include: Food & Beverage ($685,563), Consulting ($1.6M), Research ($25.2M), Travel & Lodging ($775,729).
TG Therapeutics, Inc. is associated with 2 products in the CMS Open Payments database.